Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 13, 2025
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 13, 2025
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, …
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
GlobeNewswire
·
May 13, 2025
Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include …
New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy
GlobeNewswire
·
May 13, 2025
Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated …
Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
GlobeNewswire
·
May 13, 2025
– Data from oral presentation supported ABO-101 IND and CTA approval for clinical assessment in primary hyperoxaluria type 1 (PH1) in the Phase 1/2 redePHine study in US and UK (NCT06839235) – Preclinical data demonstrate highly specific and durable …
NewBiologix Presents New Data at ASGCT on the Effective Manufacturing of rAAV-based therapeutics
GlobeNewswire
·
May 13, 2025
LAUSANNE, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- NewBiologix, a next-generation biotechnology company pioneering the future of recombinant adeno-associated virus (rAAV) production through a unique DNA-based platform built on stable cell line …
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 13, 2025
~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the …
Ring Therapeutics Presents New Data on its AnelloBricks® Manufacturing Platform at the 28th Annual American Society of Gene & Cell Therapy Conference
GlobeNewswire
·
May 13, 2025
AnelloBricks is a promising in vitro approach to producing a new class of functional viral vectors, offering dramatic advantages in manufacturing scalability and cost compared to existing vector systems Payload versatility of AnelloVectors® widens the …
The Ensign Group to Present at the 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
·
May 13, 2025
SAN JUAN CAPISTRANO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and …
RevoluGen and ProteoQuest Join Forces to Bring Fire Monkey HMW-DNA Extraction to China and Asia Pacific’s Fast Growing DNA Sequencing-based Genomics Markets
GlobeNewswire
·
May 13, 2025
HADFIELD, United Kingdom and HONG KONG, May 13, 2025 (GLOBE NEWSWIRE) -- UK genomics tools company, RevoluGen Limited and Hong Kong-based life sciences distributor ProteoQuest Technology Co. Ltd are pleased to announce they have entered into an agreement …
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025
GlobeNewswire
·
May 13, 2025
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025 EBX-102 was well tolerated and showed multiple positive trends over placebo Findings support progression to a Phase 2b trial Glasgow, Scotland – 13 May 2025. EnteroBiotix Limited (‘ …
TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing
GlobeNewswire
·
May 13, 2025
HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, announces it has raised USD 25.6 million (EUR 22.6 million) in a Series B financing …
Eleva Appoints Donato Spota as Chief Financial Officer
GlobeNewswire
·
May 13, 2025
Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. …
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease
GlobeNewswire
·
May 13, 2025
Herantis Pharma Plc – Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying …
EG 427 highlights at ASGCT major advances made with its HERMES platform in neurology using versatile non-replicative herpes vectors
GlobeNewswire
·
May 13, 2025
Data highlights advantages of single, non-replicative HSV-1 (nrHSV-1) vector hosting two transgenes with independent expression kinetics Vectors also show high transduction rate of neurons in the CNS at very low doses and can be efficiently distributed to …
EG 427 présente à l’ASGCT des avancées majeures réalisées avec sa plateforme HERMES en neurologie, démontrant la polyvalence de ses vecteurs herpétiques non-réplicatifs
GlobeNewswire
·
May 13, 2025
Les données montrent les avantages d'un vecteur HSV-1 non réplicatif (nrHSV-1) unique intégrant deux transgènes présentant des cinétiques d'expression indépendantes. Ces vecteurs transduisent efficacement les neurones du SNC à de très faibles doses et …
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
GlobeNewswire
·
May 13, 2025
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing …
Galapagos kondigt een strategische update aan over de geplande splitsing, de transitie van het uitvoerend leiderschap, en wijzigingen in de Raad van Bestuur
GlobeNewswire
·
May 13, 2025
Galapagos heroverweegt uitvoering van eerder aangekondigde splitsing naar aanleiding van ontwikkelingen in regelgeving en de markt Galapagos onderzoekt alle strategische alternatieven voor haar bestaande activiteiten, waaronder celtherapie, met de nadruk …
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Relate
GlobeNewswire
·
May 13, 2025
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Related Disorders The …
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich
GlobeNewswire
·
May 13, 2025
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic …
Arialief Reviews and Complaints 2025: What Science Says About This Neuropathy Relief Supplement (EXPOSED)
GlobeNewswire
·
May 13, 2025
FINDLAY, Ohio, May 13, 2025 (GLOBE NEWSWIRE) -- For years, I've explored every avenue for neuropathy relief—countless supplements, treatments promising quick fixes, and prescriptions that often left me disappointed. When I first encountered Arialief, a …